person
Juan M. L.
- Country
- Spain
- Department
- Department of oncology
Research Overview
assignment
12
Clinical Trials ·
- A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
- A Phase 3 Study of MK-2870 Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced or Metastatic Urothelial Carcinoma
- Phase 3 Study of Vepugratinib and Combination Therapy in Adults with Untreated FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma
location_city
2
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
121
Sites with multiple studies
Has run more than one trial at 121 of 284 partner sites.
Specializations
Melanoma Specialization
The investigator focuses on advanced treatments for metastatic and unresectable melanoma, particularly involving innovative immunotherapy approaches and targeted therapies.
- BRAF V600E/K mutation-positive melanoma
- Combination immunotherapy strategies
- Post-surgical melanoma treatment
Solid Tumor Research
Extensive work in treating various advanced solid tumors with particular emphasis on novel therapeutic combinations and immunotherapy-based approaches.
- Urothelial carcinoma
- Renal cell carcinoma
- Sarcoma variants
Immunotherapy Innovation
Leading research in novel immunotherapy treatments and their combinations with established therapeutic approaches.
- Tumor Infiltrating Lymphocytes (TIL)
- Checkpoint inhibitor combinations
- Targeted molecular therapies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.